Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to recombi...

Full description

Saved in:
Bibliographic Details
Main Authors: Scott McComb, Mehdi Arbabi-Ghahroudi, Kevin A. Hay, Brian A. Keller, Sharlene Faulkes, Michael Rutherford, Tina Nguyen, Alex Shepherd, Cunle Wu, Anne Marcil, Annie Aubry, Greg Hussack, Devanand M. Pinto, Shannon Ryan, Shalini Raphael, Henk van Faassen, Ahmed Zafer, Qin Zhu, Susanne Maclean, Anindita Chattopadhyay, Komal Gurnani, Rénald Gilbert, Christine Gadoury, Umar Iqbal, Dorothy Fatehi, Anna Jezierski, Jez Huang, Robert A. Pon, Mhairi Sigrist, Robert A. Holt, Brad H. Nelson, Harold Atkins, Natasha Kekre, Eric Yung, John Webb, Julie S. Nielsen, Risini D. Weeratna
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
chimeric antigen receptors
CD22
CAR-T
nanobody
single-domain antibody
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329924000171
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items